These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 38704515)

  • 21. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Charting new paradigms for CAR-T cell therapy beyond current Achilles heels.
    Li Y; Hu Z; Li Y; Wu X
    Front Immunol; 2024; 15():1409021. PubMed ID: 38751430
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adoptive therapy with CAR redirected T cells for hematological malignancies.
    Li S; Yang Z; Shen J; Shan J; Qian C
    Sci China Life Sci; 2016 Apr; 59(4):370-8. PubMed ID: 27009302
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CAR T Cell Therapy for Hematological Malignancies.
    Yang X; Wang GX; Zhou JF
    Curr Med Sci; 2019 Dec; 39(6):874-882. PubMed ID: 31845217
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy.
    Han X; Wang Y; Wei J; Han W
    J Hematol Oncol; 2019 Nov; 12(1):128. PubMed ID: 31783889
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse effects in hematologic malignancies treated with chimeric antigen receptor (CAR) T cell therapy: a systematic review and Meta-analysis.
    Luo W; Li C; Zhang Y; Du M; Kou H; Lu C; Mei H; Hu Y
    BMC Cancer; 2022 Jan; 22(1):98. PubMed ID: 35073859
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies.
    Liu Y; Peng C; Ahad F; Ali Zaidi SA; Muluh TA; Fu Q
    Recent Pat Anticancer Drug Discov; 2024; 19(5):557-572. PubMed ID: 38213150
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
    Khan AN; Asija S; Pendhari J; Purwar R
    Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The underlying mechanism of chimeric antigen receptor (CAR)-T cell therapy triggering secondary T-cell cancers: Mystery of the Sphinx?
    Zhou Z; Zhang G; Xu Y; Yang S; Wang J; Li Z; Peng F; Lu Q
    Cancer Lett; 2024 Aug; 597():217083. PubMed ID: 38925363
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Primer on Chimeric Antigen Receptor T-cell Therapy: What Does It Mean for Pathologists?
    Cushman-Vokoun AM; Voelkerding KV; Fung MK; Nowak JA; Thorson JA; Duncan HL; Kalicanin T; Anderson MW; Yohe S
    Arch Pathol Lab Med; 2021 Jun; 145(6):704-716. PubMed ID: 33237994
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Recent findings on chimeric antigen receptor (CAR)-engineered immune cell therapy in solid tumors and hematological malignancies.
    Keshavarz A; Salehi A; Khosravi S; Shariati Y; Nasrabadi N; Kahrizi MS; Maghsoodi S; Mardi A; Azizi R; Jamali S; Fotovat F
    Stem Cell Res Ther; 2022 Sep; 13(1):482. PubMed ID: 36153626
    [TBL] [Abstract][Full Text] [Related]  

  • 33. FDA-approved CAR T-cell Therapy: A Decade of Progress and Challenges.
    Ong MZ; Kimberly SA; Lee WH; Ling M; Lee M; Tan KW; Foo JB; Yow HY; Sellappans R; Hamzah S
    Curr Pharm Biotechnol; 2024; 25(11):1377-1393. PubMed ID: 39034731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nanotechnology and immunoengineering: How nanotechnology can boost CAR-T therapy.
    Nawaz W; Xu S; Li Y; Huang B; Wu X; Wu Z
    Acta Biomater; 2020 Jun; 109():21-36. PubMed ID: 32294554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chimeric antigen receptor T cell (CAR-T) immunotherapy for solid tumors: lessons learned and strategies for moving forward.
    Li J; Li W; Huang K; Zhang Y; Kupfer G; Zhao Q
    J Hematol Oncol; 2018 Feb; 11(1):22. PubMed ID: 29433552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end?
    Drougkas K; Karampinos K; Karavolias I; Koumprentziotis IA; Ploumaki I; Triantafyllou E; Trontzas I; Kotteas E
    J Cancer Res Clin Oncol; 2023 Jun; 149(6):2709-2734. PubMed ID: 36564524
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.
    Strati P; Neelapu SS
    Curr Oncol Rep; 2019 Mar; 21(5):38. PubMed ID: 30919158
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent Advances in CAR-T Therapy.
    Ali MB
    Cancer Control; 2024; 31():10732748241263713. PubMed ID: 38910268
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Off-the-shelf Vδ1 gamma delta T cells engineered with glypican-3 (GPC-3)-specific chimeric antigen receptor (CAR) and soluble IL-15 display robust antitumor efficacy against hepatocellular carcinoma.
    Makkouk A; Yang XC; Barca T; Lucas A; Turkoz M; Wong JTS; Nishimoto KP; Brodey MM; Tabrizizad M; Gundurao SRY; Bai L; Bhat A; An Z; Abbot S; Satpayev D; Aftab BT; Herrman M
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34916256
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chimeric antigen-receptor T-cell therapy for hematological malignancies and solid tumors: Clinical data to date, current limitations and perspectives.
    Gauthier J; Yakoub-Agha I
    Curr Res Transl Med; 2017 Sep; 65(3):93-102. PubMed ID: 28988742
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.